scimus quid non scimus
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MedolifeRx Value will Rocket Overnite Once the FDA IND For Ezcozine® is Approve...from the Mouth of the CEO Himself Dr. AM.
Listen to His Answer of the Last Question @ around 47:00 time frame of the
CC Q&A Portion
https://vimeo.com/555299590
It's a Win Win Situation.
Actually it's good for New entrants and more than Good for more Cheappy shares to LongTerm Holders still Accumulating like myself.
Right...I see them on L2,This is Nuts.Anyhoo,June 15,2021 is coming Fast.
Thanks JM for the Link...this IS Great for those Who missed to Listened and Participated during Q&A portion.I missed the end part too.
0.16 is more probable tomorrow.jmwq
Southern X Confirmed. OTC Chart can be thrown out here...but just a reminder,that an OTC Play did a Great Super Run last year from a Nickle to $4+ in just over a month,after the GG X was established and also did a CC. then pps corrected to about $2.50 then resumed the Bull Run to $9+ again in about 30 trading days.and the SS is similar with QNTA.
If you are one those bagholders under a Dime n held with a Diamond Hands...then u know n understand what talking about.
The many Catalyst here are just Truly Astonishing.
Knowing the Bio's of the Management Team was the First Part of my In-Depth DD of MedolifeRx.
I learned about it on Twitter first.
I was Intrigued by The Team Exceptional Backgrounds in Academics...so I went
on Searching and Digging for Xbones in PinkyLand but to No Avail.
Then I moved on to get some Glimpse about the Patented Polarization Technology to Produce Escozine-HP Escozine®,Clinical Research and Successes in Human Trials in DR and USA...All these has met all my Profound Criterias to Selectively Invest on a Rare and Particular OTC.
The Future of MedolifeRx is Astronomical,The Pandemic World needs it.
As a Current Shareholder and Bagholder,my Investment here will be Greatly Rewarded.
As Mentioned on the CC Top 15 Celebrities Who Use and Endorse CBD Products...
Who Will Fit the Bill?
https://cbdvsmedicine.com/15-celebrities-who-use-and-endorse-cbd-products/
Note:
The Above Mentioned CN were "Not" Discussed or Mentioned during the CC
It's just an Imaginary Assumption for the time being.
https://quantrx.com/
Pinterest
7.9k followers
16.8k following
1.9k monthly views
https://www.pinterest.com/qntatech/_created/
CEO Dr.Arthur Mikaelian is Hispanic? Did u even bother reading his Bio?
https://ir.quantrx.com/company-information/management-team
Truly Impressive and Kind of a Nasdaq CC Indeed. MedolifeRx will Rise as a Household/Brand Name Company Sooner than Later.
Missed the CC,But Tx Anyhoo DL to all the Infos'.eom
Darn it I can't Join the Q&A as I have a very Important Call Buss In-Coming @ 2:30PM.
Okey Guys Post if your Question will e Answered.etc
BRB in 30 mins.
Great CC.Future is Huge in BSV demand,Multi-Million Dollars/Month.eom
Right...and We All want to Hear them say something.I submitted a Question
it's regarding the FND IND Submission...Why No Response from the FDA yet.
If you are a ShareHolder,Register now and MedolifeRx will respond to your email provided by you.
They want you to submit a "Question" that you want to hear answered.
I did.
https://zoom.us/webinar/register/WN_gfcQmH6PQCujWCOQjIRwyA
PB is The True Master here when it Comes to things like S-1 OS.eom
Will Continue to Accumulate in 25K -50K Blocks,500K AON will not be Filled.
Just Purchased another Block of 50K X 0.0750 with Fidelity.Filling the Bag for LongTerm Hold.
Great Time to Accumulate more Shares while still very-very Cheap and as the Cryps2's are Bubbling down.Big Pharmas will come eating the Whole Pizza-Enchilada sooner or later.jmhtto
What a Stellar and Great CEO: Doing things a lot better compared to a lot of Nasdaq Listed Companies,updating the Shareholder Community regularly/consistently with their accomplishments.
Registered.You too,as a Shareholder,Do it as This is the Day to get an answer for your Question.
Great 1st QR with Medolife CEO Dr. Arthur Mikaelian...
Medolife Rx Reports First Quarter 2021 Financial and Operational Results, Schedules Conference Call with Investment Community
https://finance.yahoo.com/news/medolife-rx-reports-first-quarter-130000990.html
First Quarter 2021 Highlights:
Total revenue generated was USD $318,807;
Gross margins remained above 90%;
Cash on hand at the end of the quarter was over USD $300,000, a substantial increase when compared to the same period in the prior year;
Various positive updates on preclinical studies completed on its lead drug candidate Escozine® demonstrating safety and efficacy of the product;
Preparation for response to Pre-Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA);
Expansion of first-of-its-kind scorpion reservation and research facility in the Dominican Republic (DR), preparing for demand created by product registration of Escozine® in the region;
Rebranding efforts on nutraceutical product lines focused on major markets such as beauty, wellness and nutritional supplements;
Participate and Ask a Question during the CC.
https://zoom.us/webinar/register/WN_gfcQmH6PQCujWCOQjIRwyA
FDA IND Approved...
SCPS:PPS Jumps 71.98% Today
May 24,2021
Scopus BioPharma Announces FDA Approval of IND Application for Lead Drug Candidate
https://finance.yahoo.com/news/scopus-biopharma-announces-fda-approval-133000399.html
April 26,2021
Scopus BioPharma Announces IND Submission to FDA for Lead Drug Candidate
https://finance.yahoo.com/news/scopus-biopharma-announces-ind-submission-132500201.html
This Proves that the FDA IND Submission Date to The ApprovalDate is in "Calendar Days" and Not Business Days.
So,for QNTA,it's been over 30 Calendar Days since April 13,2021
Medolife Rx Submits Final Data Set to FDA for IND Filing on Lead Drug Candidate
https://finance.yahoo.com/news/medolife-rx-submits-final-data-123000200.html
Wake Up early if you are still waiting to BuyBack-in.You Wishaaa!!!Woulldddaa Coullddaaaa.
Escozine™ RationalWiki...
https://rationalwiki.org/wiki/Escozine
The history of Escozine starts in 2004 when founder and CEO of Medolife Dr. Arthur Grant Mikaelian started investigating the health benefits of Caribbean Blue Scorpion (Rhopalurus junceus) venom.
By 2010 he had patented a polarization process meant to improve the delivery of either minerals extracted from a peptide of the venom, or the peptide itself.
It was registered in the Dominican Republic in 2010 and half a dozen countries since,(currently 40 Countries) but despite claims of studies in conjunction with the Moores Cancer Center at UC San Diego, it is not marketed as anything other than a dietary supplement in the United States.
If you are Newbie,Go through All the PR's below link...to understand before posting a Question
https://finance.yahoo.com/quote/QNTA?p=QNTA&.tsrc=fin-srch
MedolifeRx Got the Whole Pizza Enchilada...
:Patented Polarization Technology (United States patent # 8,097,284 B2)
:Over a Decade of Research and Clinical Trials in DR and US of A
:Sprawling Blue Scorpion Reservation
:Extraction Lab Facilities
:Production
:Distribution
:Ezcozine-HP available in 40 Countries
:Quanta Products Available on Amazon,Pinterest Facebook etc.
:Awaiting FDA IND Designation (PIND #150335) Approval of Escozine® for
Essential Distribution in the US of A.
:Huge Order of Immunapen recently
:Over $1M in 2020
:Adding more SKU's this Summer
:Sustainable Blue Scorpion Venom @ $39M/Gl
https://finance.yahoo.com/news/medolife-rx-submits-final-data-123000200.html
True Sharky...aPlenty of Catalyst indeed.GM All,2morrow.eom
Right
Do u even UNDERSTAND the Word "BREAKS GROUND" means?
Did the PR mentioned about CONSTRUCTION?
It's Like your Mouth is Moving Sideways while Mumbling.
The 250sqm=2,700sqft is The New Lab Facility 1D10T..Reread the News below
Medolife Rx Breaks Ground on Lab Facility and Increases Scorpion Count at First-of-Its-Kind Reservation in the Dominican Republic
https://finance.yahoo.com/news/medolife-rx-breaks-ground-lab-120000521.html
The Blue Scorpion Reservation is a Sprawling 50,000sqm=522,720sqft = 12Acres
Expanded another 6,350sqm=68350sqft=1.56 Acre
Medolife Rx Furthers Expansion of Scorpion Reservation; Prepares for Mass Production of Escozine Required Upon Product Registration
https://finance.yahoo.com/news/medolife-rx-breaks-ground-lab-120000521.html
FDA WARNING COVID-19 PART 2 Date Issued: May 19, 2021
https://www.fda.gov/medical-devices/safety-communications/antibody-testing-not-currently-recommended-assess-immunity-after-covid-19-vaccination-fda-safety
Recommendations for People Who Had or May Have a SARS-CoV-2 Antibody Test
Be aware that SARS-CoV-2 antibody tests help health care providers identify whether someone has antibodies to SARS-CoV-2, the virus that causes COVID-19, indicating a prior infection with the virus. However, more research is needed to understand the meaning of a positive or negative antibody test, beyond the presence or absence of antibodies, including in people who received a COVID-19 vaccination, in people who have been exposed and have SARS-CoV-2 antibodies, and in people who are not fully vaccinated.
If you have not been vaccinated: Be aware that a positive result from an antibody test does not mean you have a specific amount of immunity or protection from SARS-CoV-2 infection. If you have a positive test result on a SARS-CoV-2 antibody test, it means that it is possible you were previously infected with the SARS-CoV-2 virus. Talk with your health care provider about the meaning of your SARS-CoV-2 antibody test results.
If you received a COVID-19 vaccination: Continue to follow the CDC’s recommendations for fully vaccinated people. Be aware that if you have a positive test result on a SARS-CoV-2 antibody test, it is possible you were previously infected with SARS-CoV-2. A COVID-19 vaccination may also cause a positive antibody test result for some but not all antibody tests. You should not interpret the results of your SARS-CoV-2 antibody test as an indication of a specific level of immunity or protection from SARS-CoV-2 infection. Talk to your health care provider or your state and local health departments if you have questions about whether an antibody test is right for you.
Recommendations for Health Care Providers
At this time, do not interpret the results of qualitative, semi-quantitative, or quantitative SARS-CoV-2 antibody tests as an indication of a specific level of immunity or protection from SARS-CoV-2 infection after the person has received a COVID-19 vaccination. While a positive antibody test can indicate an immune response has occurred (seroconversion), and failure to detect such a response may suggest a lack of immune response, more research is needed. Currently authorized SARS-CoV-2 antibody tests are not validated to evaluate specific immunity or protection from SARS-CoV-2 infection. SARS-CoV-2 antibody tests should be ordered only by health care providers who are familiar with the use and limitations of the test. For more information about antibody tests for SARS-CoV-2, see Serology/Antibody Tests: FAQs on Testing for SARS-CoV-2.
Be aware that vaccines trigger antibodies to specific viral protein targets. For example, currently authorized COVID-19 mRNA vaccines induce antibodies to the spike protein and not to nucleocapsid proteins that are likely detected only after natural infections. Therefore, COVID-19 vaccinated people who have not had previous natural infection will receive a negative antibody test result if the antibody test does not detect the antibodies induced by the COVID-19 vaccine. If you are considering antibody testing in vaccinated individuals, follow the Centers for Disease Control and Prevention’s guidelines for antibody testing. For more information about antibody test performance visit EUA Authorized Serology Test Performance.
Potential Risks of Improperly Using SARS-CoV-2 Antibody Test Results
Antibodies are proteins created by your body’s immune system soon after you have been infected or vaccinated. SARS-CoV-2 antibody or serology tests look for antibodies in a blood sample to determine if an individual has had a past infection with the virus that causes COVID-19. These types of tests cannot be used to diagnose a current infection. For more information about antibody testing, see Antibody (Serology) Testing for COVID-19: Information for Patients and Consumers.
Test results from currently authorized SARS-CoV-2 antibody tests should not be used to evaluate a person’s level of immunity or protection from COVID-19. If the results of the antibody test are interpreted as an indication of a specific level of immunity or protection from SARS-CoV-2 infection, there is a potential risk that people may take fewer precautions against SARS-CoV-2 exposure. Taking fewer precautions against SARS-CoV-2 exposure can increase their risk of infection and may result in increased spread of SARS-CoV-2.
FDA Actions
The FDA will continue to monitor the use of authorized SARS-CoV-2 antibody tests for purposes other than identifying people with an immune response to SARS-CoV-2 from a recent or prior infection.
The FDA provided updated information about SARS-CoV-2 antibody tests and will continue to keep health care providers and the public informed if new additional information becomes available. The FDA also provides information on Antibody (Serology) Testing for COVID-19: Information for Patients and Consumers and will update the page if new additional information becomes available.
Reporting Problems
If you think you had a problem with a SARS-CoV-2 antibody test, the FDA encourages you to report the problem through the MedWatch Voluntary Reporting Form.
Health care personnel employed by facilities that are subject to the FDA's user facility reporting requirements should follow the reporting procedures established by their facilities.
Questions?
If you have questions, email the Division of Industry and Consumer Education (DICE) at DICE@FDA.HHS.GOV or call 800-638-2041 or 301-796-7100.
FDA WARNING...COVID-19 Part 1 Date Issued: May 19, 2021
Antibody Testing Is Not Currently Recommended to Assess Immunity After COVID-19 Vaccination: FDA Safety Communication
https://www.fda.gov/medical-devices/safety-communications/antibody-testing-not-currently-recommended-assess-immunity-after-covid-19-vaccination-fda-safety
Date Issued: May 19, 2021
The U.S. Food and Drug Administration (FDA) is reminding the public and health care providers that results from currently authorized SARS-CoV-2 antibody tests should not be used to evaluate a person’s level of immunity or protection from COVID-19 at any time, and especially after the person received a COVID-19 vaccination.
While a positive antibody test result can be used to help identify people who may have had a prior SARS-CoV-2 infection, more research is needed in people who have received a COVID-19 vaccination.
Currently authorized SARS-CoV-2 antibody tests have not been evaluated to assess the level of protection provided by an immune response to COVID-19 vaccination. If antibody test results are interpreted incorrectly, there is a potential risk that people may take fewer precautions against SARS-CoV-2 exposure. Taking fewer steps to protect against SARS-CoV-2 can increase their risk of SARS-CoV-2 infection and may result in the increased spread of SARS-CoV-2.
The FDA is providing additional information and recommendations to the public and health care providers about the use of antibody tests in people who received a COVID-19 vaccination.
NDC:National Drug Code List: Escozine-HP
https://ndclist.com/ndc/70891-201#google_vignette
https://ndclist.com/drug-index/substance/escozine-hp
https://www.findacode.com/ndc/drugs/Escozine_HP
https://techneprize.com/escozine-profiled-in-abcs-fusion-news-report-story-features-medolife-ceo-dr-mikaelian/
https://www.youtube.com/channel/UCadhDn9ij-_clZof7euj4bA/featured
Certainly Correcta Mundo DL...
COVID-19 All Over the World...Flaring up once again..
https://www.msn.com/en-us/news/world/philippines-won-t-disclose-covid-shot-brand-until-appointment-to-overcome-preferences/ar-AAKcC2U?ocid=msedgntp
Escozine® will Help Mitigate the Problem.
QNTA.eom
FDA IND when Approved...the FDA will designate IND status for Escozine®, essentially allowing the drug to be distributed in the US.
https://finance.yahoo.com/news/medolife-rx-submits-final-data-123000200.html
After such designation, the Company will pursue other clinical applications of Escozine®, including as a potential cancer therapeutic where the Company has already released positive clinical results.
Ask Mr.Google to Xnslate it for you (other Language)...if u r having a problem reading and understanding it.
It is written in American not English.me thinks.
The Pandemic World needs Escozine®...
https://www.msn.com/en-us/news/coronavirus?ocid=msedgntp
Vax & Scratch' lottery scheme aims to up New York COVID-19 shots
https://www.msn.com/en-us/news/us/vax-scratch-lottery-scheme-aims-to-up-new-york-covid-19-shots/ar-AAKcHDC?ocid=msedgntp
Most Middle Class and Affluent People...not willing to get Vaccinated (Injected).
Escozine® PhII hct won't take very per the recent News.
Are you really that Naive and Antiquated still looking through a Xtall Ball in a dark-room for TradeCasting? Come on...Try Quantum instead.
A recent Business Insider article estimated scorpion venom to be the most expensive liquid in the world, valued at $39 million dollars-per-gallon.
Scorpion venom is currently in active research by large pharmaceutical companies for its therapeutic use in treating cancer, COVID-19, viral diseases, inflammation, and pain, all of which are independently multi-billion-dollar industries.
Medolife is a pioneer in venom-to-drug development.
With Medolife's Dominican Republic Scorpion Reservation being one of the largest natural breeding grounds for scorpions on earth.
Medolife will bring its 30+ years of research and expertise to help locate, study and develop groundbreaking formulas and pharmaceutical-grade medications for consumer use.